Literature DB >> 19723255

DTC advertising harms patients and should be tightly regulated.

Peter Lurie1.   

Abstract

Like all interventions in health care, direct-to-consumer (DTC) advertising should be evaluated by comparing its risks to its benefits, in the context of the available or potentially available alternatives. The objective, of course, is to realize any unique benefits while minimizing the risks. On balance, the adverse effects of DTC advertising outweigh the still-undemonstrated benefits of the advertising.

Entities:  

Mesh:

Year:  2009        PMID: 19723255     DOI: 10.1111/j.1748-720X.2009.00405.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  6 in total

1.  Is there a doctor in the house? : The presence of physicians in the direct-to-consumer genetic testing context.

Authors:  Heidi Carmen Howard; Pascal Borry
Journal:  J Community Genet       Date:  2011-09-06

2.  Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.

Authors:  Hyosun Kim
Journal:  Int J Health Policy Manag       Date:  2015-08-25

3.  Reforming direct-to-consumer advertising.

Authors:  Bryan A Liang; Tim Mackey
Journal:  Nat Biotechnol       Date:  2011-05       Impact factor: 54.908

4.  Regulating Direct-to-Consumer Drug Information: A Case Study of Eli Lilly's Canadian 40over40 Erectile Dysfunction Campaign.

Authors:  Jean-Christophe Bélisle Pipon; Bryn Williams-Jones
Journal:  Healthc Policy       Date:  2015-05

5.  An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs.

Authors:  Janelle Applequist; Jennifer Gerard Ball
Journal:  Ann Fam Med       Date:  2018-05       Impact factor: 5.166

6.  Communicating wisely: teaching residents to communicate effectively with patients and caregivers about unnecessary tests.

Authors:  Geetha Mukerji; Adina Weinerman; Sarah Schwartz; Adelle Atkinson; Lynfa Stroud; Brian M Wong
Journal:  BMC Med Educ       Date:  2017-12-11       Impact factor: 2.463

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.